Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.55 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5329597 | 0.88 | OPRM1 (0.62) | OPRM1OPRK1OPRL1OPRD1HTR2C | |
| SCHEMBL5962828 | 0.87 | HSD17B10 (0.68) | OPRM1OPRK1OPRL1OPRD1HSD17B10 | |
| SCHEMBL21634299 | 0.85 | HSD17B10 (0.62) | OPRM1OPRK1OPRL1OPRD1HTR2C | |
| SCHEMBL318707 | 0.84 | HSD17B10 (0.65) | OPRM1OPRK1OPRL1OPRD1HTR2C | |
| SCHEMBL1761014 | 0.82 | OPRL1 (0.64) | OPRM1OPRK1OPRL1OPRD1HTR2C | |
| SCHEMBL13853705 | 0.81 | OPRK1 (0.58) | OPRM1OPRK1OPRL1OPRD1HTR2C | |
| SCHEMBL14263125 | 0.81 | CCR3 (0.57) | OPRM1OPRK1OPRL1OPRD1HTR2C | |
| SCHEMBL21634315 | 0.81 | HSD17B10 (0.60) | OPRM1OPRK1OPRL1OPRD1HTR2C | |
| SCHEMBL14543210 | 0.81 | HSD17B10 (0.60) | OPRM1OPRK1OPRL1OPRD1HSD17B10 | |
| SCHEMBL13925107 | 0.80 | OPRK1 (0.59) | OPRM1OPRK1OPRL1OPRD1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | OPRM1 45/4885OPRK1 41/4885OPRL1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.